HopeStage
Back to all studies
CompletedNCT00908154

Repeated doses of GSK1014802: safety in people with bipolarity

About this titleRead the official source — NCT00908154
Medication studyAges 18–55United Kingdom
The study in practice

Understand this study

Who was this study for?

This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations
LondonSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: May 31, 2008
Recruitment status
Completed
Enrollment listed in the registry
51
Sponsor
Biogen
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 18 Years to 55 Years
Official registry ID
NCT00908154
Official title
Show the full official title

Single-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802 and Its Interaction With Food in Healthy Volunteers

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

London

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Biogen.

Did this study involve medication?

Yes. The study involved medication, including Placebo and GSK1014802.

Who was this study for?

This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies